Back to Search
Start Over
Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study
- Source :
- Farmacia Hospitalaria; November-December 2022, Vol. 46 Issue: 6 p372-379, 8p
- Publication Year :
- 2022
-
Abstract
- The cardiovascular disease is the first cause of deaths in patients with diabetes mellitus 2. The objective is to evaluate and compare the weight loss in patients with diabetes treated with the different GLP-1 receptor agonists for the first time. Secondary endpoints are glycosylated hemoglobin reduction, changes in quality of life and physical activity and the safety of these drugs.
Details
- Language :
- English
- ISSN :
- 11306343
- Volume :
- 46
- Issue :
- 6
- Database :
- Supplemental Index
- Journal :
- Farmacia Hospitalaria
- Publication Type :
- Periodical
- Accession number :
- ejs63782353
- Full Text :
- https://doi.org/10.7399/fh.13215